NEW YORK, Sept. 6 Globally, approximately 418 billionpeople are currently infected with hepatitis, and the unrecognized importance,danger, and costs of hepatitis in the 21st century cannot be understated orunderestimated, according to Global Hepatitis Strategies, a new report byKalorama Information.
Paradoxically, despite the obvious crisis, world governments are nottaking the necessary steps to contain hepatitis. Yet the incidence andprevalence of hepatitis have begun to rise in certain parts of the globalcommunity, and even industrialized nations are lacking hepatitis controlpolicies. Moreover, there is a greater crisis in hepatitis screening,diagnosis, and treatment emerging, particularly in those areas where HIV/AIDSis becoming more prevalent.
Kalorama Information estimates that the theoretical global market for allhepatitis testing products and therapeutics in 2006, assuming that aggressivescreening were to be conducted, would be $3.3 trillion, with the westernPacific and southeast Asia showing the greatest need. However, the estimatedrealistic market potential for the various global regions for 2006, based ontheir currently reported hepatitis status and pricing structure, fell farshort, reaching just $326 million.
"The strategic concept of hepatitis diagnosis and therapy is one of themost insufficiently recognized areas that the healthcare industry has everseen," notes Kenneth. G. Krul, PhD, the report's author. "Governments, withthe exception of a limited few, seem unable or unwilling to devisecomprehensive hepatitis containment and prevention policies. In order to copewith the challenges and opportunities of hepatitis diagnostics andtherapeutics, companies must think on a global basis, focusing on three pointsfor the development of strategy: potential market, epidemiology (hepatitispatient trends), and technology."
Global Hepatitis Strategies focuses on the factors that influence policyaspects of hepatitis, the options presented, the factors associated withstrategic market development of hepatitis diagnostics and therapeutics, andprospects for the future. The report analyzes strategic market effects ofepidemiology, market potential and technology, trends in epidemiology, andsocial/political attitudes towards hepatitis. This report can be purchaseddirectly from Kalorama Information by visiting:https://www.kaloramainformation.com/Global-Hepatitis-Strategies-1517677. Itis also available at MarketResearch.com.
About Kalorama Information
Kalorama Information supplies the latest in independent market research onmedical markets. For more information, contact Tom Ehart at 240-747-3014 [email protected]
, or visit www.KaloramaInformation.com.
SOURCE Kalorama Information